Equillium Inc (EQ): Strong Buy Rating and High Growth Potential in Autoimmune Therapeutics
Equillium Inc (EQ) is a clinical-stage biotechnology company that has been garnering attention from Wall Street analysts, with a consensus rating of “Strong Buy” based on recent reports. The company specializes in developing novel therapeutics to treat severe autoimmune and inflammatory disorders, which is a high-need area in the medical field. Market Trend for Equillium (EQ)… Read More »Equillium Inc (EQ): Strong Buy Rating and High Growth Potential in Autoimmune Therapeutics









